INPDL BioPharma announced that it has priced a $300 million securitization transaction intended to monetize certain of its antibody humanization patents and royalties.

Upon closing of the transaction, which is expected to occur on  Nov. 2, BioPharma will sell to QHP Royalty Sub,  a newly-formed wholly-owned subsidiary of BioPharma, certain rights under its non-exclusive license agreements with Genentech, a wholly-owned subsidiary of Roche Holding.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.